Kerendia 10mg (Finerenone) – Benefits & Specifications Kerendia (Finerenone) 10mg is a nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) used to reduce the risk of kidney disease progression and cardiovascular complications in patients with chronic kidney disease (CKD) associated with type 2 diabetes. Key Benefits of Kerendia 10mg: Protects Kidney Function: Helps slow the decline of kidney function in patients with CKD and type 2 diabetes. Reduces Cardiovascular Risk: Lowers the risk of heart failure, heart attacks, and other cardiovascular complications. Anti-Inflammatory & Anti-Fibrotic Effects: Reduces inflammation and fibrosis in the kidneys and heart. Potassium Management: Unlike steroidal MRAs, finerenone has a lower risk of hyperkalemia while still being effective. Clinically Proven: Supported by clinical trials such as the FIDELIO-DKD and FIGARO-DKD studies, which show significant benefits for patients with CKD and type 2 diabetes
- Protects Kidney Function: Helps slow the decline of kidney function in patients with CKD and type 2 diabetes.
- Reduces Cardiovascular Risk: Lowers the risk of heart failure, heart attacks, and other cardiovascular complications.
- Anti-Inflammatory & Anti-Fibrotic Effects: Reduces inflammation and fibrosis in the kidneys and heart.
- Potassium Management: Unlike steroidal MRAs, finerenone has a lower risk of hyperkalemia while still being effective.
- Clinically Proven: Supported by clinical trials such as the FIDELIO-DKD and FIGARO-DKD studies, which show significant benefits for patients with CKD and type 2 diabetes
Reviews
There are no reviews yet.